BMY Bristol Myers Squibb Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NYSE: BMY
  4. Earnings
?
Relative Growth: Rel. Growth: 60
Relative Strength: Rel. Strength: 31
Relative Valuation: Rel. Valuation: 89
Relative Profitability: Rel. Profitability: 97

EPS in 2025 (TTM): $2.97

Last Report Period Date: Sep 30, 2025

According to the most recent financial data from September 2025, the current EPS (TTM) is $2.97. Bristol Myers Squibb's EPS for 2024 came in at -$4.41, marking a decrease from $3.88 in 2023. For the quarterly period ending on Sep 30, 2025, BMY's EPS was $1.08.

BMY earnings history

Historical annual and quarterly earnings per share (EPS) data for Bristol Myers Squibb
EPS (TTM)
$2.97
EPS Growth YoY (Quarterly)
80%
EPS (Quarterly)
$1.08
EPS Growth (Quarterly)
68.8%

Bristol Myers Squibb had an annual EPS of -$4.41, marking a decrease of 213.7% from $3.88 in 2023. The quarterly EPS for the period ending Sep 30, 2025, was $1.08, marking a 80% increase from the same quarter last year. BMY's TTM EPS stands at $2.97 as of September 2025. Bristol Myers Squibb's EPS for 2023 stood at $3.88, a 30.6% increase from 2022.

BMY EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
80%
EPS growth YoY
-213.7%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Bristol Myers Squibb has recorded an increase in EPS of 80% over the last 12 months (YoY, quarterly).

BMY Earnings Waterfall

Breakdown of revenue, profit and net income for Bristol Myers Squibb

BMY Earnings vs Peers

What are the earnings of BMY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MRK Merck & Co Inc 12.98 4,728.6% 9.4% 12%
PFE Pfizer Inc 14.31 273.7% -28.7% -13.2%
ABT Abbott Laboratories 15.57 133.8% 24.5% 29.9%
BMY Bristol Myers Squibb Co 15.65 -213.7% N/A N/A
NVS Novartis AG 17.03 -17.2% -17.9% 2.9%
JNJ Johnson & Johnson 17.83 -57.9% -9.7% 0.4%
AMGN Amgen Inc 24.55 -39.3% -9.7% -10.1%
AZN Astrazeneca plc 30.28 18.2% 284.3% 34.3%
LLY ELI LILLY & Co 45.18 102.1% 24.1% 5.7%
ABBV AbbVie Inc 162.98 -12.1% -28.2% -14.7%

All data is based on quarterly TTM periods, unless otherwise specified.